Plasma exosome microRNA novel-3 and its antagonists and applications
By developing plasma exosomal miRNA novel-3 and its antagonists, the challenges of predicting and treating patients with atherosclerotic acute cerebral infarction have been addressed, enabling effective assessment and improvement of neurological deficits and inflammation.
Patent Information
- Application Number
- CN202310556526.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-05-17
AI Technical Summary
Current technologies lack effective biomarkers and treatments for patients with atherosclerotic acute ischemic stroke (AS-AIS), especially drugs for predicting neurological deficits and improving symptoms.
We developed plasma exosomal miRNA novel-3 and its antagonist. The nucleotide sequence of novel-3 is ucaggccaggcugggaggaugc. It was chemically modified to be fully methylated and linked to a high-affinity cholesterol modification at the 3' end. It was used to prepare kits and drugs to target miRNAs to improve neurological deficits.
Novel-3 can predict neurological deficits, infarct size, and neuroinflammation after cerebral infarction. Novel-3 antagonists improve neurological function and produce neuroprotective effects by reducing infarct size and inhibiting microglial cell activation.
Smart Images

Figure HDA0004233283590000011 
Figure HDA0004233283590000012 
Figure HDA0004233283590000021
Abstract
Description
Technical Field
[0001] The present invention relates to the field of stroke drugs, and in particular to a plasma exosome microRNA novel-3 and an antagonist thereof and application thereof. Background Art
[0002] Acute ischemic stroke (AIS), also known as cerebral infarction, refers to a disease in which local arterial blood perfusion in the brain is reduced or interrupted, leading to tissue necrosis. It has three major characteristics: high morbidity, high disability rate, and high mortality rate. It is an important cause of death and disability worldwide. Due to its acute onset, short optimal treatment time window, severe clinical symptoms and poor prognosis, it has become a heavy burden on individuals and society. At present, intravenous thrombolysis and vascular interventional thrombectomy have become the main treatment methods in clinical practice, but both have very strict time window restrictions (within a few hours of onset). Therefore, a large number of AIS patients still cannot receive effective treatment in time within the time window for various reasons. Atherosclerosis (AS) is a common complication and risk factor of cerebral infarction, among which large artery atherosclerotic cerebral infarction has clinical characteristics such as severe onset and poor prognosis. Therefore, new drugs need to be developed for the treatment of AIS patients with AS, especially the development of treatment methods that can effectively improve the neurological deficits of AS-AIS patients.
[0003] Exosomes are microvesicle structures with a diameter of 40-150nm, which can carry DNA, RNA, proteins, lipids and other substances, and are widely present in the extracellular matrix and body fluids. The microRNA (miRNA) carried by exosomes plays an important role in intercellular communication and can participate in the pathogenesis of AS and AIS through intercellular signaling. Current research evidence shows that exosomal miRNA plays a role in the occurrence of stroke and neural repair, and its expression level changes significantly after cerebral ischemia. However, there is currently no report on the development of exosome-related biomarkers for patients with cerebral infarction, an important subtype of AS-AIS, and its application in its diagnosis and treatment.
[0004] MiRNA antagonists are specially chemically modified miRNA antagonists that strongly competitively bind to mature miRNAs in the body, preventing the complementary pairing of miRNAs with their target gene mRNAs and inhibiting the function of miRNAs. The Chinese invention patent with publication number CN105251008A discloses the use of miRNA-155 antagonists in the preparation of drugs for the treatment of scleroderma, suggesting the feasibility of developing antagonists against miRNAs for the treatment of AS-AIS. Although there are currently some different applications of miRNA antagonists in the treatment of diseases, there are no reports on the use of related antagonists as an important subtype of cerebral infarction, AS-AIS.
[0005] Therefore, it is of great clinical significance to discover an exosome-related miRNA biomarker that can effectively predict neurological deficits after the onset of AS-AIS, a subtype of cerebral infarction. At the same time, the development of specific antagonists and targeted intervention of miRNA carried by exosomes can be used as a potential therapeutic drug to improve the neurological deficit symptoms of AS-AIS patients. Summary of the invention
[0006] The purpose of the present invention is to overcome the shortcomings of the prior art, and provide a plasma exosomal miRNA novel-3 (hereinafter referred to as novel-3) and its antagonist and application, novel-3 is used as a biomarker to prepare a kit for predicting neurological deficits after acute cerebral infarction or predicting the area of infarction lesions or predicting neuroinflammation; an antagonist of novel-3 is developed, and the role of the novel-3 antagonist in the preparation of a drug for treating atherosclerotic acute cerebral infarction is determined.
[0007] To achieve the above purpose, the technical solution designed by the present invention is as follows:
[0008] The present invention provides an application of plasma exosome novel-3 in preparing a kit for evaluating neurological deficit after cerebral infarction, predicting infarction area after cerebral infarction and predicting the severity of neuroinflammation after cerebral infarction. The nucleotide sequence of the plasma exosome novel-3 is ucaggccaggcugggaggaugc, as shown in SEQ ID NO: 1.
[0009] The present invention also provides a novel-3 antagonist, whose nucleotide sequence is gcauccucccagccuggccuga, as shown in SEQ ID NO:2.
[0010] Furthermore, the novel-3 antagonist is a chemically modified nucleotide sequence.
[0011] Furthermore, the chemical modification is a methylation modification of the entire chain, with 2 and 4 bases thio-modified at the 5' end and 3' end respectively, and a high-affinity cholesterol modification connected at the 3' end.
[0012] The present invention also provides a use of the novel-3 antagonist in the preparation of a drug for treating neurological deficits, infarct area and microglia-mediated neuroinflammatory damage caused by acute ischemic stroke.
[0013] The medicine comprises an effective amount of novel-3 antagonist and pharmaceutically acceptable excipients. The dosage form of the medicine is injection, and the excipient is enzyme-free water. The content of the novel-3 antagonist is 50 nmol.
[0014] Beneficial effects of the present invention
[0015] 1. The plasma exosome novel-3 of the present invention is used as a biomarker to prepare a kit for predicting neurological deficits after acute cerebral infarction, predicting the area of infarction lesions and predicting neuroinflammation;
[0016] 2. Antagonists targeting novel-3 can improve the symptoms of acute ischemic stroke by improving neurological deficits after acute ischemic stroke, reducing infarct size, and alleviating the degree of microglial activation and neuroinflammation mediated by it. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is the expression level diagram of novel-3 in the two groups of exosomes;
[0018] Figure 2 Statistical graphs of the paw slipping rate (left) and mNSS score (right) of mice injected with low / high expression of novel-3 exosomes;
[0019] Figure 3 The correlation analysis diagrams of plasma exosome novel-3 expression levels with claw slip rate (left figure) and mNSS score (right figure);
[0020] Figure 4 The statistical graphs show the percentage of infarct area in mice injected with low / high expression of novel-3 exosomes;
[0021] Figure 5 This is a correlation analysis chart of plasma exosome novel-3 expression level and infarct area ratio;
[0022] Figure 6 Statistical graphs of microglial density (left) and firmness (right) in mice injected with low / high expression of novel-3 exosomes;
[0023] Figure 7 The graphs are the correlation analysis between plasma exosome novel-3 expression level and microglial density (left figure) and firmness (right figure);
[0024] Figure 8 Statistical graphs of the paw sliding rate (left graph) and mNSS score (right graph) after injection of novel-3 antagonist / control;
[0025] Fig. 9 This is a statistical chart of the percentage of infarct area after injection of novel-3 antagonist / control;
[0026] Fig.10 Statistical graphs of microglial cell density (left) and firmness (right) after injection of novel-3 antagonist / control;
[0027] Fig.11 This is a statistical chart of the changes in mRNA levels of various inflammation-related indicators after novel-3 antagonists were used to treat microglia;
[0028] In the figure, A is the Nlrp3 expression level graph, B is the IL-1b expression level graph, C is the TGFb expression level graph, and D is the IL-10 expression level graph. DETAILED DESCRIPTION
[0029] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand.
[0030] Example 1 Plasma exosome novel-3 and neurological deficits after cerebral infarction
[0031] In this example, the predictive significance of plasma exosome novel-3 on neurological deficits after cerebral infarction was observed, and the specific method was as follows:
[0032] C57BL / 6J wild-type mice aged 8-10 weeks were used. The right internal carotid artery was occluded with a suture for 1 hour under anesthesia, and the embolus was removed. Transient middle cerebral artery occlusion (MCAO) was used to establish an animal model of cerebral infarction. Exosomes with high novel-3 expression and low novel-3 expression ( Figure 1 ) were injected into two groups of MCAO mice, and their neurological deficits were observed.
[0033] The neural injury of mice after MCAO was evaluated by behavioral experiments, including the sliding paw test and mNSS score.
[0034] 1) The paw slip test is a behavioral experiment to detect the loss or recovery of the motor function of the forepaws of mice after stroke. The number of times the left forepaw of the mouse slips into the gap of the grid while the mouse walks 20 steps on the grid is recorded, and the ratio of the two is the error rate of the mouse paw slip test. The more times the mouse falls, the higher the error rate, indicating that its motor function is worse.
[0035] 2) The mNSS score is a score for evaluating the neurological deficits of mice by comprehensively evaluating the tail lifting test, walking test, sensory test, balance beam test, reflexes and abnormal activities of mice. The mNSS score of normal mice is 0, the score of mice with mild neurological damage is 1-6, the score of mice with moderate neurological damage is 7-12, and a score of 12 or above indicates severe neurological damage.
[0036] The results showed that in the group injected with highly expressed novel-3 exosomes, the number of mouse claw slips increased and the mNSS score was higher ( Figure 2 ). This indicates that the expression level of exosome novel-3 is closely related to neurological impairment after cerebral infarction, and the level of plasma exosome novel-3 can be used as a potential biomarker for predicting neurological impairment after cerebral infarction. The nucleotide sequence of plasma exosome novel-3 is ucaggccaggcugggaggaugc, as shown in SEQ ID NO:1.
[0037] Further correlation analysis was performed between plasma exosome novel-3 levels and the severity of neurological deficits in the MCAO mouse model. The results showed that the number of falls in the MCAO mouse sliding paw test was positively correlated with novel-3 levels (R 2 =0.7010, p<0.0001), and the mNSS score of MCAO mice was positively correlated with the level of novel-3 (R 2 =0.7587, p<0.0001). Therefore, plasma exosome novel-3 can be used as a biomarker to predict the severity of neurological damage after cerebral infarction ( Figure 3 ).
[0038] Example 2 Plasma exosome novel-3 levels predict infarct size after cerebral infarction
[0039] This example observes the predictive significance of plasma exosome novel-3 levels on infarct area after cerebral infarction, and the specific method is as follows:
[0040] Transient middle cerebral artery occlusion (MCAO) was used to establish an animal model of cerebral infarction. Exosomes expressing novel-3 and novel-3 were injected into two groups of MCAO mice, respectively, and Nissl staining was used to detect the cerebral infarction area.
[0041] Nissl staining is a method of staining nerve tissue with alkaline dyes, and is widely used to show changes in the area of cerebral infarction. Nissl bodies are a type of basophilic substance in the cytoplasm, which is widely distributed in various neurons. The shape, size, and number of Nissl bodies in different neurons vary. Nissl staining can stain Nissl bodies, which are used to observe the cell structure in neurons. The damage to neurons can also be understood by observing Nissl bodies. Normal tissue is stained blue, and the infarct is light-colored. The infarct area is measured using ImageJ software.
[0042] The results showed that the proportion of infarct area increased significantly in the group injected with highly expressed novel-3 exosomes ( Figure 4 ). This indicates that the expression level of exosome novel-3 is closely related to the infarct size after cerebral infarction, and the level of exosome novel-3 can be used as a potential biomarker to predict the infarct size after cerebral infarction.
[0043] Further correlation analysis was performed between plasma exosome novel-3 levels and the proportion of infarct area in MCAO mouse models. The results showed that the infarct area of MCAO mice was positively correlated with novel-3 levels (R 2 =0.5025, p=0.0021). Therefore, plasma exosome novel-3 can be used as a biomarker to predict infarct size after cerebral infarction ( Figure 5 ).
[0044] Example 3. Plasma exosome novel-3 levels predict the severity of neuroinflammation after cerebral infarction
[0045] This example observes the predictive significance of plasma exosome novel-3 levels on the severity of neuroinflammation after cerebral infarction. The specific method is as follows:
[0046] Transient middle cerebral artery occlusion (MCAO) was used to establish an animal model of cerebral infarction. Exosomes with high and low novel-3 expression were injected into two groups of MCAO mice, respectively, to observe the degree of microglial activation.
[0047] As the innate immune cells of the central nervous system, the activation of microglia plays an important role in mediating neuroinflammation, and its highly activated state can release high levels of proinflammatory factors and cytotoxic substances, thereby causing neuronal disability and cell death. The morphology of microglia is closely related to its function. Under normal circumstances, the microglial cell bodies in the resting state are relatively small and highly branched. When brain tissue neuroinflammation is obvious, microglia are gathered in large numbers near the lesion tissue, and the cell bodies increase and the protrusions shorten. The activation of microglia can be described from the aggregation degree and firmness (cell area / protrusion area) of microglia, and the increased cell density indicates that it is activated and gathered near the lesion, and the higher the firmness, the larger the cell body area, the shorter the protrusions, and the more activated the cells are. In the present embodiment, the activation degree of microglia was analyzed by observing Iba-1 (a classical biomarker of microglia) by immunofluorescence staining.
[0048] The results showed that in the group injected with highly expressed novel-3 exosomes, microglia became denser, more solid, and significantly activated ( Figure 6 ). This indicates that the expression level of exosomal novel-3 is closely related to microglia-mediated neuroinflammation after cerebral infarction, and the level of exosomal novel-3 can be used as a potential biomarker to predict neuroinflammation after cerebral infarction.
[0049] The correlation analysis between plasma exosome novel-3 levels and the degree of microglial activation in MCAO mouse models was further performed. The results showed that the density of microglial cells in MCAO mice was positively correlated with the level of novel-3 (R 2 =0.4185, p = 0.0068), microglial firmness in MCAO mice was positively correlated with novel-3 levels (R 2 =0.5461, p=0.0011). Therefore, plasma exosome novel-3 can be used as a biomarker to predict the severity of neuroinflammation after cerebral infarction ( Figure 7 ).
[0050] Example 4 Antagonist sequences and modification methods
[0051] The nucleotide sequence of the novel-3 antagonist is gcauccucccagccuggccuga;
[0052] The negative control sequence is uuuguacuacacaaaaguacug; the novel-3 antagonist is the reverse complementary sequence of the mature chain of miRNA novel-3; wherein the novel-3 antagonist is methylated throughout the entire chain, has 2 and 4 base thiolation modifications at the 5' end and 3' end, respectively, and is connected to a high-affinity cholesterol modification at the 3' end.
[0053] Example 5: Improvement of neurological function damage after cerebral infarction by novel-3 antagonist
[0054] A classic method was used to construct an atherosclerosis mouse (AS) model: ApoE knockout mice were fed a high-fat diet for 12 weeks. Blood samples were collected from AS mice, and AS exosomes were obtained by differential-ultracentrifugation. The classic transient middle cerebral artery occlusion (MCAO) method was used to establish an acute cerebral infarction mouse model. The mice after MCAO modeling were injected with AS exosomes through the tail vein for 3 consecutive days to simulate acute cerebral infarction in patients with atherosclerosis. At the same time, the mice after modeling were injected with novel-3 antagonists (50nmol) or negative controls of the same dose to observe the intervention effect of novel-3 antagonists on neurological damage in AS-MCAO mice.
[0055] The neurological damage of mice was evaluated by behavioral experiments (including the sliding claw test and mNSS score). The results showed that the number of sliding claws and mNSS scores of mice injected with novel-3 antagonists were reduced ( Figure 8 ), indicating that the neurological deficits and motor abilities of mice injected with novel-3 antagonists were improved to a certain extent. These results indicate that novel-3 antagonists can improve the neurological deficits after cerebral infarction in patients with atherosclerosis, thereby improving the prognosis of patients.
[0056] Example 6: Improvement of infarct size after cerebral infarction by novel-3 antagonist
[0057] As in Example 5, an acute cerebral infarction (AS-MCAO) mouse animal model of atherosclerosis patients was constructed, and the mice were injected with novel-3 antagonist (50 nmol) or an equal dose of negative control after modeling to observe the intervention effect of novel-3 antagonist on the infarction area of AS-MCAO mice.
[0058] Nissl staining was used to show the changes in the percentage of infarct area in mice. The results showed that the percentage of infarct area in mice injected with novel-3 antagonists was significantly reduced ( Fig. 9 ). This suggests that novel-3 antagonists can reduce the infarct area after cerebral infarction in patients with atherosclerosis, thereby producing a neuroprotective effect.
[0059] Example 7: novel-3 antagonists fight neuroinflammation after cerebral infarction and produce neuroprotective effects
[0060] As in Example 5, an acute cerebral infarction (AS-MCAO) mouse animal model of patients with atherosclerosis was constructed, and the mice were injected with novel-3 antagonist (50 nmol) or an equal dose of negative control after modeling to observe the intervention effect of novel-3 antagonist on post-infarction neuroinflammation in AS-MCAO mice.
[0061] Iba-1 is commonly used as a biomarker for microglia. Observing Iba-1 by immunofluorescence staining can analyze the degree of microglial activation (microglial density and firmness). The results showed that after injection of novel-3 antagonists, the number of microglia in the lesions of cerebral infarction decreased (density decreased) and firmness decreased, indicating that their activation was significantly weakened ( Fig.10 ). This suggests that novel-3 antagonists can inhibit the degree of microglial activation, indicating that the antagonists can reduce microglia-mediated neuroinflammatory damage after cerebral infarction in patients with atherosclerosis, and play a protective role against neuroinflammation as a potential therapeutic drug.
[0062] Example 8 Primary cultured microglia verify the effect of novel-3 antagonists against microglia-mediated neuroinflammation
[0063] In order to verify the antagonistic effect of novel-3 antagonists on microglia-mediated neuroinflammation in vitro, this example uses novel-3 antagonists and their negative controls to intervene in primary cultured microglia in vitro to verify the inhibitory effect of novel-3 inhibitors on microglial neuroinflammation; the specific method is as follows:
[0064] Primary cultured microglia were cultured to a good state and then inoculated into cell well plates. The classic glucose-oxygen deprivation / reoxygenation (OGD / R) model was used to simulate the ischemic and hypoxic environment of acute ischemic stroke in mice: the culture medium was replaced with sterile PBS, and the microglia were placed in an incubator with an oxygen concentration of 1% for 4 hours of hypoxia to perform glucose-oxygen deprivation; after the end of hypoxia, the liquid in the well plate was replaced with a high-glucose culture medium containing serum, and the well plate was placed in a normal incubator with an oxygen concentration of 5% and continued to be cultured for 24 hours.
[0065] Primary cultured microglia were treated with novel-3 antagonist (50 nmol / L) and its negative control 48 hours before glucose-oxygen deprivation. After 24 hours of reoxygenation, the cells were lysed with Trizol, RNA was extracted, and the expression levels of microglial inflammatory factors were detected by real-time quantitative PCR.
[0066] The classic view is that activated microglia can secrete a variety of inflammatory factors, play a pro-inflammatory role, aggravate inflammatory damage, and promote the progression of the disease; classic pro-inflammatory indicators include: NOD-like receptor pyrin domain-related protein 3 (Nlrp3), interleukin 1b (IL-1b), etc. Microglia can also secrete anti-inflammatory cytokines that contribute to neuroprotection. Classic anti-inflammatory indicators include: transforming growth factor b (TGFb), interleukin (IL-10), etc. By detecting these inflammation-related indicators, the inflammatory phenotype of microglia and its corresponding functions can be reflected.
[0067] Specifically, in this example, the expression levels of these different indicators were detected by PCR to monitor the functional changes of microglia after novel-3 antagonist treatment. Specific indicators and corresponding primer sequences include:
[0068] Gene Upstream primer Downstream primer β-Actin TGGAATCCTGTGGCATCCATGA AATGCCTGGGTACATGGTGGTA Nlrp3 ATTACCCGCCCGAGAAAGG TCGCAGCAAAGATCCACACAG IL-1b GAAATGCCACCTTTTGACAGTG TGGATGCTCTCATCAGGACAG TGF CTTCAATACGTCAGACATTCGGG GTAACGCCAGGAATTGTTGCTA IL-10 GGCAGAGAACCATGGCCCAGAA AATCGATGACAGCGCCTCAGCC
[0069] The results showed that the microglial inflammation-related indicators (Nlrp3, IL-1b) after novel-3 antagonist treatment were significantly decreased compared with the negative control group, while the related indicators of inhibiting inflammation (TGFb, IL-10) were significantly increased compared with the negative control group ( Fig.11 ). This suggests that novel-3 antagonists can reduce the pro-inflammatory damage of microglia and promote the expression of anti-inflammatory factors in microglia, thereby exerting a neuroprotective effect. This also suggests the potential of novel-3 antagonists as a therapeutic drug after cerebral infarction.
[0070] In summary, novel-3 antagonists can be used as a therapeutic drug to improve the symptoms of neurological deficits after cerebral infarction, reduce the area of infarction, inhibit microglial activation and its mediated neuroinflammation, and promote the release of neuroprotective factors, thereby exerting a neuroprotective effect. This further suggests its potential as a clinical therapeutic drug for cerebral infarction.
[0071] Although the above embodiments have been described in detail, they are only a part of the embodiments of the present invention, not all of them. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all belong to the protection scope of the present invention.
Claims
1. A novel-3 antagonist, Features: The novel-3 antagonist is a nucleotide sequence modified by methylation throughout the entire chain, and its nucleotide sequence is shown in SEQ ID NO: 2; there are 2 and 4 base thiolation modifications at the 5' and 3' ends of the sequence, respectively, and a high-affinity cholesterol modification is connected at the 3' end.
2. Use of the novel-3 antagonist according to claim 1 in the preparation of a medicine for treating acute ischemic stroke.
3. The use according to claim 2, Features: The acute ischemic stroke is acute ischemic stroke of large artery atherosclerosis type.
4. Use of the novel-3 antagonist according to claim 1 in the preparation of a medicament for treating neurological deficits, infarct size and microglia-mediated neuroinflammatory damage caused by acute ischemic stroke.
Citation Information
Patent Citations
Application of Micro RNA-155 antagonist in preparation of drug for treating scleroderma
CN105251008A
Use of microRNA in exosomes for diagnosis of cerebral arterial thrombosis
CN108070650A
Methods of using microrna 195 in providing neuroprotection
US20140294943A1
Novel human mirnas for use in diagnosis, prognosis, and therapy of human conditions and diseases
US20170009295A1
